# Dimension Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dimension-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.dimensiontx.com
- Total disclosed funding: $90M
- Latest round: Series B (Apr 20, 2015)
- Investors on record: 7

## About

Dimension Therapeutics Inc is a biotechnology company focused on developing innovative gene therapies to treat rare diseases, leveraging advanced technologies to transform patient care.Dimension Therapeutics Inc, founded in 2013 in Cambridge, US, specializes in gene therapy products targeting rare diseases. The company has successfully raised funds through four deals, with the most recent being an IPO on October 22, 2015, which raised USD 71.5 mn. The company was established by a team of individuals with extensive backgrounds in biotechnology and pharmaceuticals.Dimension Therapeutics focuses on delivering innovative gene therapies, targeting genetic disorders through advanced biotechnological solutions. Its product pipeline includes therapies that address critical unmet medical needs in rare diseases, ensuring enhanced patient outcomes and improvements in quality of life.In the fiscal year 2016, Dimension Therapeutics reported a revenue of USD 11.47 mn. However, the company experienced a negative EBITDA amounting to USD -47.36 mn during the same year, reflecting the challenges faced in the biotechnology sector as it invests heavily in research and development.Dimension Therapeutics aims to expand its product offerings with the development of new gene therapies targeting additional rare diseases expected to enter clinical trials by 2024. The company plans to utilize the funds raised from the IPO to accelerate its research initiatives and support the expansion into new markets across Europe and Asia, particularly targeting healthcare systems in Germany and Japan by late 2025.

## Funding rounds

- Series B, Apr 20, 2015, $65M — OrbiMed Advisors, New Leaf Venture Partners, F-Prime Capital, Jennison Associates, RA Capital Management, Rock Springs Capital, Partner Fund Management
- Series A, Feb 11, 2015, $20M — OrbiMed Advisors, F-Prime Capital
- Series A, Oct 31, 2013, $5M — F-Prime Capital

## Investors

- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series B
- Jennison Associates — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Rock Springs Capital — Series B
- Partner Fund Management — Series B